The findings are similar to a recently published paper that shows that from 2016 to 2020, the 1L treatment approach for advanced NSCLC in the US evolved from anti-PD-1/PD-L1 monotherapy to combination chemo-immunotherapy, alongside a rise in biomarker testing (47). This evidence concerns the gene CD274 and non-small cell lung carcinoma.